Comparative Pharmacology
Head-to-head clinical analysis: ABITREXATE versus GEMCITABINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABITREXATE versus GEMCITABINE HYDROCHLORIDE.
ABITREXATE vs GEMCITABINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate, the active ingredient, is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby blocking the conversion of dihydrofolate to tetrahydrofolate, inhibiting DNA synthesis, repair, and cellular replication. It also has immunosuppressive and anti-inflammatory effects via modulation of adenosine and cytokine pathways.
Gemcitabine is a nucleoside analog that inhibits DNA synthesis. It is phosphorylated intracellularly to active diphosphate and triphosphate metabolites. The diphosphate inhibits ribonucleotide reductase, reducing deoxynucleotide pools, while the triphosphate competes with deoxycytidine triphosphate for incorporation into DNA, causing masked chain termination and apoptosis.
7.5 mg orally once weekly; alternatively, 7.5 mg subcutaneously once weekly. Dose may be increased by 2.5 mg every 1-2 weeks up to 20 mg once weekly based on response and tolerability.
1000 mg/m² IV over 30 minutes on days 1 and 8 of a 21-day cycle, or 1250 mg/m² IV over 30 minutes on days 1 and 8 of a 21-day cycle.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours (mean 7.5 hours) in patients with normal renal function; prolonged in renal impairment.
Short terminal half-life (~8-17 min) for parent drug; prolonged 14-18 h for triphosphate active metabolite intracellularly in peripheral blood mononuclear cells; clinical context necessitates prolonged infusion schedules.
Primarily renal (80-90% as unchanged drug) via glomerular filtration and active tubular secretion; biliary/fecal excretion accounts for <10%.
Primarily renal: 92-98% of administered dose excreted unchanged in urine; <1% excreted in feces; <5% as inactive metabolite 2',2'-difluorodeoxyuridine.
Category C
Category D/X
Antimetabolite
Antimetabolite